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BACKGROUND: Choline and betaine, similar to folate, are nutrients involved in one-carbon metabolism and hypothesised to reduce
breast cancer risk. No prospective study among post-menopausal women has examined choline and betaine intakes in relation to
breast cancer risk.
METHODS: We examined the intake of choline and betaine and breast cancer risk among 74584 post-menopausal women in the
Nurses’ Health Study. Nutrient intake was assessed using a validated food-frequency questionnaire six times since 1984. During
20 years of follow-up from 1984 until 2004, we documented 3990 incident cases of invasive breast cancer.
RESULTS: Overall, choline (mean±s.d.; 326±61mg per day) and betaine (104±33mg per day) intake was not associated with a
reduced risk of post-menopausal breast cancer. Participants in the highest quintile of intakes had multivariate relative risks of 1.10
(95% confidence interval (95% CI): 0.99–1.22; P-value, test for trend¼0.14) for choline and 0.98 (95% CI: 0.89–1.09; P-value, test
for trend¼0.96) for betaine, compared with those in the lowest quintiles of intakes. The results were similar in breast cancer
stratified by hormone receptor (oestrogen receptor/progesterone receptor) status. The association between choline intake and
breast cancer risk did not differ appreciably by alcohol intake (non-drinker, o15 or 15þ g per day) or several other breast cancer
risk factors, including family history of breast cancer, history of benign breast disease, body mass index, post-menopausal hormone
use, and folate intake.
CONCLUSION: We found no evidence that higher intakes of choline and betaine reduce risk of breast cancer among post-menopausal
women.
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Choline and betaine are nutrients involved in one-carbon
metabolism, a network of biochemical reactions that transfer
methyl groups from one compound to another (Mason, 2003).
One-carbon metabolism is involved in the methylation of DNA and
RNA and subsequently influences gene stability and expression.
One-carbon metabolism also mediates nucleotide synthesis; thus,
perturbation of the metabolism may lead to chromosomal breaks
and disruption of DNA repair. Choline can convert to betaine,
which can donate the methyl group to homocysteine as does folate,
although the donation of the methyl group by betaine is limited to
the liver and the kidney. Although two meta-analyses did not find
an overall association between folate intake and breast cancer risk
(Lewis et al, 2006; Larsson et al, 2007), in some studies, folate
intake was inversely associated with breast cancer risk in the whole
population (Ericson et al, 2007), or among alcohol drinkers (Zhang
et al, 1999; Rohan et al, 2000), or with certain hormone receptor
types of breast cancer (Zhang et al, 2005; Larsson et al, 2008;
Maruti et al, 2008). Choline and betaine may reduce the risk of
breast cancer in a manner similar to that of folate. Despite the
potential importance of choline and betaine in carcinogenesis, few
epidemiological studies have evaluated the relationship between
intakes of choline and betaine in relation to cancer risk. A case–
control study found that choline intake was associated with a
reduced risk of breast cancer (Xu et al, 2008). However, a
prospective study did not find any associations between these
nutrients and risk of pre-menopausal breast cancer (Cho et al,
2007a). To our knowledge, no prospective study has examined
choline and betaine intakes in relation to breast cancer risk among
post-menopausal women. We therefore examined intakes of these
nutrients in relation to breast cancer risk in a large cohort of post-
menopausal women.
MATERIALS AND METHODS
Study population
In 1976, we enrolled 121700 female registered nurses aged 30–55
years in the Nurses’ Health Study (NHS) (Colditz and Hankinson,
2005). Biennial follow-up questionnaires were sent to the women
to update information regarding diet and other lifestyle-related
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sfactors and to ascertain new diagnoses of major illnesses, including
breast cancer. Deaths in the cohort were ascertained by reports
from family members, from the postal service, and from a search
of the National Death Index. We estimate that more than 98% of
deaths were ascertained through these sources (Stampfer et al,
1984). The overall follow-up for this cohort is 90%. We considered
women who reported that their menstrual periods ceased or
underwent bilateral oophorectomy as post-menopausal. Women
who reported menstrual cessation after undergoing a simple
hysterectomy or removal of only one ovary or those who did not
report the reason for cessation were considered post-menopausal
when they reached the age at which natural menopause had
occurred in 90% of the cohort (54 years for a current smoker and
56 years for a non-smoker). We limited the analysis to 37374
women who were post-menopausal in 1984 and added otherwise
eligible women as they became post-menopausal during follow-up.
Thus, a total of 74584 women were included in the analysis.
The procedures and protocols of the study were approved by the
Institutional Review Boards of the Brigham and Women’s
Hospital.
Dietary assessment
A semi-quantitative food-frequency questionnaire (FFQ) with B60
food items was sent to the members of the cohort in 1980. An
expanded FFQ with B130 food items was administered to women
in 1984, 1986, 1990, 1994, and 1998. Participants were asked how
often, on an average, they consumed each type of food during the
past year. Serving sizes were specified for each food in the FFQ.
The questionnaire had nine possible responses, ranging from
never or less than once per month to six or more times per day.
The choline and betaine composition of individual foods was
added to the nutrient database of the FFQ (Harvard University
Food Composition Database) using values published by Zeisel et al
(2003a,b) and from the choline database of the USDA (US
Department of Agriculture, 2004). Betaine values were further
updated in 2008 after correcting the betaine content of some
common foods (breads and grains especially). The average daily
intake of choline and betaine was calculated by multiplying the
frequency of consumption of each food item by its choline and
betaine content and summing the nutrient contributions of all
foods. Total choline intake was calculated as the sum of choline
intake from free choline, phosphocholine, glycerophosphocholine,
phosphatidylcholine (lecithin), and sphingomyelin. We used the
regression-residual method to adjust nutrient intakes for total
energy intake (Willett and Stampfer, 1986). After examining the
values of choline and betaine across different FFQs, we decided to
start follow-up from 1984 because similar and more comprehen-
sive FFQs were used since then, and thus intake data were more
comparable across time.
As dietary intake may affect breast carcinogenesis over an
extended period of time, to best represent long-term intake, we
calculated cumulative averaged intakes of choline and betaine
using repeated FFQ data for our primary analysis, to reduce
measurement error in dietary assessment (Hu et al, 1999). For
example, 1984 intake was used for the 1984–1986 follow-up
period, and the average of 1984 and 1986 intake was used for the
1986–1990 follow-up to maintain a strictly prospective analysis.
Intakes of choline and betaine measured by our FFQ predicted
plasma total homocysteine levels in a cohort study of men and
women in the Framingham Offspring Study (Cho et al, 2006),
which confirmed validity and biological relevance of choline and
betaine intake measured by FFQ. For the lowest and highest
quintiles of choline intake, the multivariate geometric means for
homocysteine were 10.6 and 9.8mmoll
 1 (P for trend o0.0001),
respectively. For the lowest and highest quintiles of betaine intake,
the corresponding geometric means were 10.4 and 10.1mmoll
 1
(P for trend 0.05), respectively. The inverse association between
dietary choline and betaine intake and levels of blood homo-
cysteine was manifested primarily in participants with low folate
intake (P for interaction o0.0001); among those with a folate
intake of p250mg per day, the geometric mean homocysteine
concentrations in the lowest and highest quintiles of choline plus
betaine intake were 12.4 and 10.2mmoll
 1 (P for trend o0.0001),
respectively. Although slightly weaker, a similar inverse associa-
tion as in the Framingham Offspring Study was found between
choline plus betaine intake and plasma homocysteine levels in the
NHS. Compared with those in the lowest quintile, individuals in
the highest quintile of choline plus betaine intake had 8% lower
levels of homocysteine (Chiuve et al, 2007). Neither choline nor
betaine intake individually was significantly associated with levels
of homocysteine.
Identification of cases
Biennial questionnaires mailed between 1984 and 2004 were used
to identify newly diagnosed cases of breast cancer during follow-
up. When a case of breast cancer was reported, we asked the
participant (or next of kin for those who had died) for
confirmation of the diagnosis and for permission to seek relevant
hospital records and pathology reports. Only invasive breast
cancer cases were included in the analysis. Confirmation of
oestrogen receptor (ER) and progesterone receptor (PR) status was
obtained by reviewing pathology reports.
Statistical analysis
Participants contributed person-time from the date of return of the
1984 questionnaire until the date of breast cancer diagnosis, death,
or June 2004, whichever came first. Participants were divided into
quintiles according to their nutrient intakes. Relative risks (RRs) of
breast cancer were calculated as the incidence rate for a given
quintile of nutrient as compared with the rate for the lowest
quintile. We used Cox proportional hazards regression to account
for potential effects of other risk factors for breast cancer. To
control as finely as possible for confounding by age, calendar time,
and any possible two-way interactions between these two time
scales, we stratified the analysis jointly on the basis of age in
months at the start of follow-up and calendar year of the current
questionnaire cycle. Multivariate models also adjusted simulta-
neously for smoking status, body mass index (BMI) at age 18 years,
weight change between age 18 years and current cycle, height,
physical activity, age at menarche, family history of breast cancer,
history of benign breast disease, parity and age at first birth, post-
menopausal hormone use, and intakes of calories, total folate, and
alcohol. All covariates except BMI at age 18 years, height, age at
menarche, and family history of breast cancer were updated in
each questionnaire cycle or whenever new data were available.
We also examined the latency effect of choline and betaine
intake using multiple dietary assessments. For example, for a
latency period of 0–4 years, we used the 1984 intake for cases
diagnosed from 1984 to 1986, the 1986 intake for cases diagnosed
from 1986 to 1990, the 1990 intake for cases diagnosed from 1990
to 1994, and so on. For latency of 4–8 years, we used the 1984
intake for cases diagnosed from 1988 to 1990, the 1986 intake for
cases diagnosed from 1990 to 1994, and so on. The 0–4-year
latency analysis corresponds to the analysis using the most recent
dietary intake. Latency analyses were used to examine whether
there is a possible time lag between choline and betaine intake and
risk of breast cancer.
The SAS PROC PHREG (Cary, NC, USA) tool was used for all
analysis, and the Anderson–Gill data structure was used to handle
time-varying covariates efficiently (i.e., a new data record was
created for every questionnaire cycle at which a participant was at
risk, with covariates set to their values at the time that the
questionnaire was returned). For all RRs, 95% confidence intervals
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s(CIs) were calculated. Tests for trend were conducted using the
median value for each category of nutrient as a continuous
variable. To test whether the association between choline intake
and breast cancer risk was modified by alcohol intake, folate
intake, BMI, post-menopausal hormone use, history of benign
breast disease, and family history of breast cancer, cross-product
terms for the level of an interaction variable (continuous form for
folate and alcohol) and choline intake expressed as a continuous
variable were included in the multivariate model. The P-value for
the tests for interaction was obtained from a likelihood ratio test
with two degrees of freedom. All P-values were two-sided.
RESULTS
During 532338 person-years of follow-up of 74584 post-meno-
pausal women, we documented 3990 cases of invasive breast
carcinoma. The age range of cases at the time of diagnosis of breast
cancer was 38–82 years (mean¼64, s.d.¼7). Table 1 presents the
distribution of risk factors for breast cancer by quintiles of choline
and betaine intake in 1994, which is an approximate middle point
of the follow-up. We have chosen the time point because
participants could be added once they reach menopause after
1984, and thus the middle point of the follow-up may best
represent the whole population in the analysis. Women with higher
intake of choline were more likely to have higher BMI, higher
physical activity, and higher folate intake (Po0.05). Women with
higher intake of betaine were less likely to be smokers and more
likely to have a history of benign breast disease, lower BMI, and
higher folate intake (Po0.05). Choline intake in the NHS has
reduced over time; the mean±s.d. values for choline intake were
338±82mg per day in dietary assessment in 1984 and 298±69mg
per day in 2002, respectively. Betaine intake remained similar over
time; the mean±s.d. values for betaine intake were 106±44mg
per day in dietary assessment in 1984 and 100±43mg per day in
2002, respectively.
Higher intakes of dietary choline and betaine were not
associated with reduced breast cancer risk (Table 2). Choline
intake was associated with slightly elevated risk of breast cancer,
although not statistically significant; the multivariate RRs (95% CI)
for increasing quintiles of intake were 1.00 (referent), 1.09 (0.99–
1.21), 1.10 (1.00–1.22), 1.09 (0.98–1.20), and 1.10 (0.99–1.22;
P-value test for trend¼0.14). Betaine intake was not associated
with breast cancer risk. None of the individual sources of choline
was related to breast cancer risk. Intake of methionine, another
nutrient involved in one-carbon metabolism, was not associated
with risk of breast cancer; the RR for top vs bottom quintiles of
methionine intake was 1.08 (0.97–1.20). Intakes of choline and
betaine were not associated with risk of breast cancer in situ
(n¼736; data not shown).
Results were similar when breast cancers were grouped by
hormone receptor status. For example, the RRs for top vs bottom
quintiles of choline intake were 1.07 (0.92–1.25) for ERþ/PRþ
cancers (n¼1998), and 1.15 (0.86–1.54) for ER /PR  cancers
(n¼538). As there may be a latency effect of choline and betaine,
we took advantage of repeated assessment of dietary intake to
assess the temporal relationship between choline and betaine
intake and breast cancer risk. We evaluated latency periods of 0–4,
4–8, 8–12, 12–16, and 16–20 years. When the latency period
became longer, the modest positive association between choline
intake and breast cancer became weaker and in fact became
slightly inverse for a latency period of 16–20 years (RR for the top
vs bottom quintile of choline intake¼0.92 (0.74–1.14)). There was
no appreciable difference in association between betaine intake
and breast cancer risk by latency period.
The availability of other dietary factors related to one-carbon
metabolism, including alcohol and folate, may modify the
association between choline and breast cancer risk. We thus
examined choline intake and breast cancer risk by levels of folate
intake (o300, 300–o400, 400–o500, and X500mg per day) and
alcohol intake (non-drinker, 40–o15, and X15g per day)
(Table 3). The positive association between choline and breast
Table 1 Characteristics of the cohorts according to energy-adjusted choline and betaine intake among post-menopausal women in the Nurses’ Health
Study in 1994
a
Intake category (quintiles)
Choline Betaine
Variable 1 3 5 1 3 5
Number of participants 10195 10216 10222 10191 10245 10212
Group, %
Current smokers 13.4 12.6 13.9 17.7 13.0 9.8
History of benign breast disease 45.7 44.5 45.3 42.7 45.9 47.3
Family history of breast cancer 12.8 13.2 12.9 12.8 12.9 13.3
Current post-menopausal hormone use 41.4 44.3 43.5 40.2 44.4 45.7
Mean
Age (years) 62.2 62.2 62.7 62.9 62.0 62.6
Height (inches) 64.3 64.4 64.5 64.4 64.4 64.4
Body mass index (kgm
 2) 25.6 26.3 27.2 26.6 26.5 25.9
Physical activity (mets per week) 17.8 19.7 20.4 17.4 19.3 20.8
Age at menarche (years) 12.6 12.5 12.4 12.5 12.5 12.4
Age at first birth (years) 25.3 25.2 25.1 25.3 25.2 25.2
Parity (children) 3.1 3.1 3.1 3.1 3.1 3.1
Age at menopause (years) 47.6 47.7 47.4 47.4 47.6 47.6
Alcohol intake (g per day) 5.3 5.3 4.4 5.0 5.3 4.9
Folate intake (mg per day) 418.6 463.4 502.7 415.4 450.2 529.4
aExcept for the data on mean age, all data shown are standardised to the age distributions of the cohorts in 1994. For simplicity, only data for the first, third, and fifth quintiles of
intakes of choline and betaine are shown. All variables, except history of benign breast disease, family history of breast cancer, and parity for choline intake, and family history of
breast cancer, height, age at first birth, and alcohol intake for betaine intake, showed a significant test for trend (Po0.05).
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scancer was limited to a mid-range folate intake of 300–o500mg
per day (P-value for interaction¼0.06). The association between
choline intake and breast cancer risk did not differ appreciably by
alcohol intake (P-value for interaction¼0.31).
We also examined whether the association between intakes of
choline and betaine and breast cancer risk differed by levels of
other breast cancer risk factors, such as family history of breast
cancer (yes, no), history of benign breast disease (yes, no), BMI
(o27.5, X27.5kgm
 2), and post-menopausal hormone use
(never, past, or current) (Table 3). None of the P-values for
interaction were statistically significant. However, choline intake
was positively associated with breast cancer among those with no
history of benign breast disease (RR for the top vs bottom quintile
1.25 (95% CI: 1.07–1.46); P for trend 0.03), but not among those
with a history of benign breast disease (RR for the top vs bottom
quintile 0.98 (95% CI: 0.84–1.13); P for trend 0.98). Similarly,
choline intake was positively associated with breast cancer among
current users of post-menopausal hormone (RR for the top vs
bottom quintile 1.32 (95% CI: 1.03–1.70); P for trend 0.06), but not
among those who never used hormone or who used hormone in
the past (RR for the top vs bottom quintile 1.12 (95% CI: 0.94–
1.33); P for trend 0.17 for never users and RR for the top vs bottom
quintile 1.03 (95% CI: 0.88–1.21); P for trend 0.94 for past users).
DISCUSSION
In this large prospective study among post-menopausal women, we
did not find any strong overall associations between intakes of
choline and betaine and risk of breast cancer. The results were
Table 2 Relative risk (RR) and 95% confidence interval (CI) of breast cancer (n¼3990) according to quintile of cumulative averaged energy-adjusted
choline and betaine intake in post-menopausal women
Quintile of intake
Nutrient 1 2 3 4 5
P-value, test
for trend
Total choline
Median intake (intake range; mg per day) 260 (57–280) 294 (280–307) 319 (307–332) 346 (332–364) 396 (364–1427)
No. of cases/person-years 721/208365 821/208457 825/208667 816/208847 807/208723
Age-adjusted RR (95% CI) 1.00 1.12 (1.01–1.24) 1.12 (1.01–1.24) 1.11 (1.00–1.22) 1.12 (1.01–1.23) 0.09
Multivariate
a RR (95% CI) 1.00 1.09 (0.99–1.21) 1.10 (1.00–1.22) 1.09 (0.98–1.20) 1.10 (0.99–1.22) 0.14
Betaine
Median intake (intake range; mg per day) 71 (10–79) 86 (79–93) 99 (93–106) 114 (106–125) 144 (125–1595)
No. of cases/person-years 764/208378 786/208206 798/208644 858/208549 784/209282
Age-adjusted RR (95% CI) 1.00 1.01 (0.91–1.12) 1.02 (0.92–1.13) 1.09 (0.98–1.20) 0.98 (0.89–1.09) 0.98
Multivariate
a RR (95% CI) 1.00 1.01 (0.91–1.11) 1.01 (0.91–1.12) 1.07 (0.97–1.19) 0.98 (0.89–1.09) 0.96
Free choline
Median intake (intake range; mg per day) 58 (20–63) 66 (63–69) 72 (69–75) 79 (75–83) 90 (83–588)
No. of cases/person-years 706/208244 793/208960 829/208088 851/208888 811/208879
Age-adjusted RR (95% CI) 1.00 1.09 (0.98–1.20) 1.11 (1.10–1.23) 1.14 (1.03–1.26) 1.10 (0.99–1.21) 0.07
Multivariate
a RR (95% CI) 1.00 1.07 (0.96–1.19) 1.10 (0.99–1.21) 1.12 (1.01–1.24) 1.08 (0.97–1.21) 0.13
Choline from glycerophosphocholine
Median intake (intake range; mg per day) 33 (8–38) 42 (38–46) 50 (46–54) 59 (54–66) 77 (66–246)
No. of cases/person-years 724/208610 808/208607 765/208741 828/208530 865/208570
Age-adjusted RR (95% CI) 1.00 1.07 (0.96–1.18) 1.00 (0.90–1.11) 1.06 (0.96–1.17) 1.09 (0.99–1.21) 0.11
Multivariate
a RR (95% CI) 1.00 1.06 (0.96–1.17) 1.00 (0.90–1.10) 1.05 (0.95–1.16) 1.09 (0.98–1.20) 0.15
Choline from phosphocholine
Median intake (intake range; mg per day) 10 (0.3–11) 12 (11–13) 14 (13–15) 16 (15–18) 20 (18–92)
No. of cases/person-years 761/208510 759/208406 810/208561 805/208734 855/208848
Age-adjusted RR (95% CI) 1.00 0.96 (0.87–1.06) 1.01 (0.92–1.12) 0.99 (0.89–1.09) 1.04 (0.94–1.15) 0.33
Multivariate
a RR (95% CI) 1.00 0.96 (0.86–1.06) 1.02 (0.92–1.13) 0.99 (0.89–1.10) 1.05 (0.95–1.17) 0.23
Choline from phosphatidylcholine
Median intake (intake range; mg per day) 121 (18–133) 143 (133–152) 159 (152–168) 178 (168–192) 217 (192–967)
No. of cases/person-years 795/208353 820/208581 817/208598 770/208898 788/208630
Age-adjusted RR (95% CI) 1.00 1.03 (0.93–1.13) 1.04 (0.94–1.14) 0.99 (0.90–1.09) 1.04 (0.94–1.15) 0.65
Multivariate
a RR (95% CI) 1.00 1.02 (0.92–1.12) 1.03 (0.93–1.14) 0.98 (0.89–1.09) 1.04 (0.93–1.15) 0.70
Choline from sphingomyelin
Median intake (intake range; mg per day) 13 (0.01–14) 16 (15–17) 18 (17–19) 20 (19–21) 23 (21–90)
No. of cases/person-years 751/208238 843/208411 797/208578 827/208955 772/208877
Age-adjusted RR (95% CI) 1.00 1.13 (1.02–1.24) 1.07 (0.97–1.18) 1.12 (1.01–1.24) 1.08 (0.97–1.19) 0.24
Multivariate
a RR (95% CI) 1.00 1.11 (1.00–1.22) 1.05 (0.95–1.16) 1.09 (0.99–1.21) 1.05 (0.95–1.17) 0.45
aMultivariate model was stratified by age in months at the start of follow-up and calendar year of the current questionnaire cycle and was simultaneously adjusted for smoking
status (never, past, and current 1–14, 15–24, and 25 cigarettes per day), height (o63, 63–o64, 64–o66, 66+ inches), parity and age at first birth (nulliparous, parity p2, and
age at first birth o25 years, parity p2 and age at first birth 25–o30 years, parity p2 and age at first birth 30+ years, parity 3–4 and age at first birth o25 years, parity 3–4 and
age at first birth 25–o30 years, parity 3–4 and age at first birth 30+ years, parity 5+ and age at first birth o25 years, parity 5+ and age at first birth 25+ years), body mass index
at age 18 (continuous), weight change between age 18 and current (o 2,  2–2, 2.1–5, 5.1–10, 10.1–20, 20.1–25, X25kg), physical activity (quintiles of metabolic
equivalents per week), age at menarche (o13, 13, X14 years), family history of breast cancer (yes, no), history of benign breast disease (yes, no), use of post-menopausal
hormones (never, past, current), and intakes of alcohol (continuous), energy (continuous), and folate (continuous).
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ssimilar in breast cancer stratified by hormone receptor status and
in the analyses stratified by several breast cancer risk factors.
Our findings on choline intake are not consistent with a case–
control study of 1508 breast cancer cases that found that higher
choline intake was associated with up to 24% lower risk of breast
cancer, although the association was not linear (P-value for
trend¼0.29) (Xu et al, 2008). The study included both pre- and
post-menopausal women and reported that the inverse association
between choline intake and breast cancer risk was not altered by
menopausal status. Betaine intake was not associated with breast
cancer risk in the study, which was in accordance with our study.
On the other hand, a large prospective study of pre-menopausal
women did not find any associations between intakes of choline
and betaine and breast cancer risk (Cho et al, 2007a). Few studies
have examined choline intake in relation to other cancer end
points (Cho et al, 2007b).
Choline and betaine are nutrients that were, until recently, not
extensively investigated in epidemiological studies because of lack of
food composition databases (Zeisel et al, 2003b). Choline and betaine
are major dietary sources of methyl groups, as is folate. Choline is
also a precursor of membrane phospholipids phosphatidylcholine
and sphingomyelin. In animal studies, a choline-deficient diet itself
can induce liver cancer in the absence of any carcinogen (Henning
and Swendseid, 1996). Nutrients responsible for one-carbon meta-
bolism, including folate and methionine, have been related to risk of
cancer of several organs in humans (Giovannucci et al, 1993; Zhang
et al, 1999; Alberg et al, 2000; Stolzenberg-Solomon et al, 2001;
Martinez et al, 2004). Humans require choline from diet because of
insufficient de novo synthesis in the body. The recommended daily
intake was set in 1998 at 550mg per day for men and 425mg per day
for women (Yates et al, 1998). Our previous data in this cohort
showed that mean choline intake in this population of females was
lower than the recommended daily intake (Cho et al, 2007b).
The positive association between choline intake and breast
cancer risk, although modest and not significant, is similar to that
which we found in relation to colorectal adenomas in this
population; we found that higher choline intake was associated
with up to 45% elevated risk of colorectal adenomas (Cho et al,
2007b). The latency analysis suggested that any positive associa-
tion was mostly due to relatively recent choline intake, suggesting
that choline may affect tumour progression, rather than tumour
initiation. Biological explanations for the positive association
may include the role of choline as a cell membrane phospholipid.
Once a tumour is initiated, proliferation of tumour may in part
depend on choline availability to generate cell membranes. In a
study of hepatocarcinogenesis in rats, animals fed a choline-
deficient diet for 3 or 6 months, followed by a choline-
supplemented diet, had a higher incidence of tumours and more
amplification of the c-myc oncogene than did animals fed a
choline-deficient diet continuously, suggesting the role of choline
in tumour development (Chandar and Lombardi, 1988; Chandar
et al, 1989). Several cancers and cancer cell lines have altered
membrane phospholipid metabolism with enhanced choline
uptake and increased choline metabolite concentrations (Mori
et al, 2004; Villa et al, 2005). Choline kinase, an enzyme converting
choline to phosphocholine, which leads to the generation of
membrane phospholipids, is elevated in human breast cancer
(Ramirez de Molina et al, 2002).
The suggestive interaction between choline and folate intake in
relation to breast cancer risk is hard to interpret, especially
because the positive association between choline intake and breast
cancer risk was mostly limited to middle-intake categories of
folate. For colorectal adenomas, we found that the positive
association between choline intake and adenoma risk was the
strongest among those with the lowest folate intake (Cho et al,
2007b).
Table 3 Multivariate relative risk (RR) and 95% confidence interval (CI) of breast cancer according to quintile of cumulative averaged energy-adjusted
choline intake by breast cancer risk factors in post-menopausal women
Quintile of intake
Breast cancer risk factor 1 2 3 4 5
P-value, test
for trend
P-value, test
for interaction
Alcohol
Non-drinker (n¼936) 1.00 1.05 (0.85–1.29) 1.15 (0.94–1.42) 1.12 (0.90–1.38) 1.15 (0.93–1.41) 0.18
o15g per day (n¼2106) 1.00 1.09 (0.95–1.26) 1.10 (0.96–1.27) 1.09 (0.95–1.26) 1.10 (0.95–1.28) 0.29
15+g per day (n¼948) 1.00 1.22 (0.99–1.50) 1.09 (0.88–1.35) 1.08 (0.87–1.34) 1.10 (0.87–1.39) 0.80 0.31
Folate
o300mg( n¼1029) 1.00 0.95 (0.79–1.13) 1.01 (0.83–1.21) 0.99 (0.81–1.21) 1.04 (0.84–1.29) 0.69
300–o400mg( n¼943) 1.00 1.13 (0.91–1.39) 1.08 (0.87–1.34) 1.03 (0.82–1.28) 1.30 (1.04–1.62) 0.07
400–o500mg( n¼722) 1.00 1.39 (1.07–1.81) 1.28 (0.98–1.67) 1.47 (1.13–1.91) 1.39 (1.05–1.83) 0.04
X500mg( n¼1296) 1.00 1.02 (0.84–1.25) 1.12 (0.92–1.36) 1.01 (0.83–1.22) 0.94 (0.78–1.14) 0.29 0.06
Post-menopausal hormone use
Never (n¼1373) 1.00 1.01 (0.84–1.20) 1.08 (0.91–1.28) 1.06 (0.89–1.26) 1.12 (0.94–1.33) 0.17
Past (n¼1840) 1.00 1.09 (0.94–1.26) 1.05 (0.91–1.22) 1.02 (0.88–1.19) 1.03 (0.88–1.21) 0.94
Current (n¼777) 1.00 1.30 (1.02–1.66) 1.25 (0.98–1.60) 1.31 (1.03–1.67) 1.32 (1.03–1.70) 0.06 0.92
History of benign breast disease
No (1877) 1.00 1.18 (1.01–1.37) 1.17 (1.00–1.36) 1.10 (0.95–1.29) 1.25 (1.07–1.46) 0.03
Yes (2113) 1.00 1.01 (0.88–1.16) 1.05 (0.91–1.20) 1.08 (0.94–1.24) 0.98 (0.84–1.13) 0.98 0.24
Body mass index
o27.5kgm
 2 (n¼2574) 1.00 1.12 (0.99–1.26) 1.05 (0.93–1.19) 1.11 (0.98–1.25) 1.10 (0.97–1.26) 0.20
X27.5kgm
 2 (n¼1406) 1.00 1.02 (0.85–1.23) 1.13 (0.94–1.35) 0.97 (0.81–1.16) 0.98 (0.82–1.18) 0.55 0.15
Family history of breast cancer
XNo (n¼3235) 1.00 1.14 (1.02–1.27) 1.09 (0.98–1.22) 1.09 (0.98–1.23) 1.09 (0.97–1.22) 0.36
XYes (n¼755) 1.00 0.94 (0.73–1.19) 1.07 (0.85–1.36) 1.04 (0.82–1.33) 1.12 (0.87–1.44) 0.25 0.42
Multivariate model was adjusted for the same covariate as Table 2.
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sThis study had several strengths. The prospective nature
of the study avoided biases of case–control studies. Our
study provided a unique opportunity to evaluate intakes of
choline and betaine in a large population of post-menopausal
women, which provided informative numbers of breast
cancer cases in several stratified analyses. As we had repeated
measures of dietary intake, we were able to examine long-term
averaged diet, as well as several latency analyses. Measurement
error is reduced by the use of repeated measures. Finally, we had
information on a wide range of potential confounders and adjusted
for them.
In conclusion, in this cohort of post-menopausal women, we
found that intakes of choline and betaine were not related to a
reduced risk of breast cancer.
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